Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688050's Debt-to-EBITDA is ranked worse than 79.62% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs SHSE:688050: 4.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Eyebright Medical Technology (Beijing) Co Debt-to-EBITDA Related Terms
Eyebright Medical Technology (Beijing) Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eyebright Medical Technology (Beijing) Co Debt-to-EBITDA Chart
Eyebright Medical Technology (Beijing) Co Annual Data
SHSE:688050 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eyebright Medical Technology (Beijing) Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Eyebright Medical Technology (Beijing) Co (SHSE:688050) has a Debt-to-EBITDA of 2.48 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eyebright Medical Technology (Beijing) Co. This is 202% above median its historical median of 0.82. Over the past decade, Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA has ranged from 0.01 to 6.74. According to the industry distribution chart, Eyebright Medical Technology (Beijing) Co ranks #375 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 79.6%.
Is Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA too high?
Eyebright Medical Technology (Beijing) Co's current Debt-to-EBITDA of 2.48 is 202% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 6.74. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Eyebright Medical Technology (Beijing) Co's value of 2.48 is 51.2% above this industry median. Based on the distribution chart, Eyebright Medical Technology (Beijing) Co ranks #375 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Eyebright Medical Technology (Beijing) Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Eyebright Medical Technology (Beijing) Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Eyebright Medical Technology (Beijing) Co ranks #375 out of 471 companies for Debt-to-EBITDA. This places Eyebright Medical Technology (Beijing) Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Eyebright Medical Technology (Beijing) Co's value of 2.48 is 51.2% above this benchmark. Historically, Eyebright Medical Technology (Beijing) Co's own Debt-to-EBITDA has ranged from 0.01 to 6.74 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 1.64, Eyebright Medical Technology (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eyebright Medical Technology (Beijing) Co's current Debt-to-EBITDA of 2.48 is 51.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Eyebright Medical Technology (Beijing) Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eyebright Medical Technology (Beijing) Co's current Debt-to-EBITDA is 2.48, which is 202% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eyebright Medical Technology (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Eyebright Medical Technology (Beijing) Co (SHSE:688050) is currently considered Possible Value Trap. The stock's GF Value™ is ¥110.11, compared to a current price of ¥37.63 — trading 65.8% below its estimated fair value. The current Debt-to-EBITDA is 2.48, which is 202% above median its 10-year median of 0.82 and 51.2% above the Medical Devices & Instruments industry median of 1.64. Eyebright Medical Technology (Beijing) Co's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Eyebright Medical Technology (Beijing) Co (SHSE:688050), the current Debt-to-EBITDA is 2.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eyebright Medical Technology (Beijing) Co (SHSE:688050) Overvalued in 2026?
Based on GuruFocus' analysis, Eyebright Medical Technology (Beijing) Co stock appears to be undervalued.
The current stock price of ¥37.63 is trading 65.8% below its estimated GF Value™ of ¥110.11.
GuruFocus considers Eyebright Medical Technology (Beijing) Co to be Possible Value Trap.
Key valuation signals for SHSE:688050:
Debt-to-EBITDA: 2.48 (202% above median its 10-year median of 0.82)
GF Value™: ¥110.11 vs. price of ¥37.63 (65.8% below fair value)
Industry Position: 51.2% above the Medical Devices & Instruments median (#375 of 471)
No single metric tells the full story. See the SHSE:688050 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eyebright Medical Technology (Beijing) Co Ltd is engaged in research and development, production, sales and related services of ophthalmic medical devices. The company's product range includes Intraocular Lens; IOL Delivery System; Ophthalmic Instruments; Other Products; Literature; and Expert Interview.
75GF Score
Get the complete analysis for SHSE:688050
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688050 has been successfully added to your 
